Results 141 to 150 of about 24,692 (192)

Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd: YAG Laser Capsulotomy for Posterior Capsule Opacification.

J Pharm Bioallied Sci
Gupta T, Kashyap R, Ganjoo S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nanoemulsion based In-situ Gel for ocular delivery of Brimonidine Tartrate

Current Drug Therapy, 2023
Brimonidine tartrate is currently used to treat glaucoma; however, conventional ocular formulations have some disadvantages in terms of treating disorders like glaucoma, as less than 5% of the drug reaches a posterior segment of the eye; hence, there ...
Bhupendra Prajapati, Uma Patel, Chetna Modi, P. Kendre   +3 more
semanticscholar   +1 more source

RP-HPLC Method Development for Simultaneous Estimation of Brimonidine Tartrate and Timolol Maleate in Ophthalmic Preparation

International Journal of Pharmaceutical Sciences and Nanotechnology, 2023
Introduction: A simple, precise, rapid, and reproducible RP-HPLC method is developed for the simultaneous estimation of brimonidine tartrate and timolol maleate present in ophthalmic dosage forms. Method: Gradient RP-HPLC is carried out at 35℃ on column
Ajay I. Patel, Anjali K Mandavia, Darshita R Vyas, A. Vyas   +3 more
semanticscholar   +1 more source

Brimonidine tartrate for the treatment of glaucoma

Expert Opinion on Pharmacotherapy, 2018
Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles, brimonidine is associated with high rates of ...
Judy L. Chen, Mark S. Dikopf, Thasarat S. Vajaranant, Daniel J. Oh   +3 more
openaire   +3 more sources

Brimonidine Tartrate

Ophthalmology, 1997
Brimonidine tartrate is a relatively selective alpha2-agonist that effectively reduces mean intraocular pressure (IOP) and the incidence of IOP spikes after laser trabeculoplasty. The authors were interested in evaluating the dose response of brimonidine when applied topically for a longer duration in patients with elevated IOPs.The authors conducted a
Howard S. Barnebey, Alan L. Robin, Kuankuan Chen, Elaine P. Kelley, T.R. Walters, Neil T. Choplin, Robert J. Derick, Joel S. Schuman, Jack F. Stoecker   +8 more
openaire   +3 more sources

Side-Effect Profile of Brimonidine Tartrate in Children

Ophthalmology, 2005
To investigate brimonidine-related side effects and the efficacy of brimonidine in lowering intraocular pressure (IOP) in children with primary infantile and secondary glaucoma.Single-center, prospective, interventional, noncomparative case series.Eighty-three children (mean age, 7.84 years) met the inclusion criteria.Medical records were reviewed to ...
Ibrahim Al-Jadaan, Shahira Turkmani, Sami Al-Shahwan, Abdullah A. Al-Torbak, Mamdouh Al-Omran, Deepak P. Edward   +5 more
openaire   +3 more sources

Advances in Glaucoma Therapy: Brimonidine Tartrate

Seminars in Ophthalmology, 1997
Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2-imidazoline derivative which is more highly selective for the α2-adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the ...
Jeffrey M. Liebmann, David S. Greenfield, Robert Ritch   +2 more
openaire   +2 more sources

Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy

Expert Review of Clinical Pharmacology, 2022
Introduction Ocular redness, or conjunctival hyperemia, is a common ophthalmic sign associated with reduced quality of life. For redness without apparent underlying pathology, topical ophthalmic decongestants have been widely used.
J. Lee, Chan-Yun Kim
semanticscholar   +1 more source

Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate

Current Drug Delivery, 2010
Micro and nanoparticulate carriers have been in focus in ophthalmic drug delivery with the objective of improving bioavailability, drug targeting and reducing pulse entry of the drug in ocular cul de sac. Polymeric nanoparticles for ocular purpose have potential in reducing the pulse entry and frequency of dosing, thus improving patient compliance.
Ujwala A Shinde, Kavita Singh
openaire   +2 more sources

Effect of Brimonidine Tartrate on Ocular Hemodynamics in Healthy Volunteers

Journal of Ocular Pharmacology and Therapeutics, 2001
While alpha2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic alpha2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow.
Jonescu-Cuypers, Christian Paul, Harris, A, Ishii, Y, Kagemann, L, Gazozi, H J, Rotenstreich, Y, Chung, H S, Martin, B   +7 more
openaire   +4 more sources